Sue-Jean Lin Buys Shares of Stevanato Group S.p.A. (NYSE:STVN)

On June 12, 2026, Sue-Jean Lin purchased 4,975 shares of Stevanato Group S.p.A. (NYSE:STVN). As of Friday, the stock traded at $18.39. The transaction did not specify a purchase price or total value.

Insider Buying and Selling at Stevanato Group S.p.A.

In addition to Sue-Jean Lin's acquisition, several other insiders were active around the same period. On June 12, 2026, Marco Dal Lago, the company's Chief Financial Officer, also bought 2,356 shares. A few days later, on June 15, 2026, insiders Karen Flynn, William Federici, Madhavan Balachandran, and Donald Morel Jr. each sold 1,493 shares at an average price of $17.09.

Other Institutional Activity in Stevanato Group

Several institutional investors have also adjusted their positions in Stevanato Group. Conestoga Capital Advisors, LLC increased its holdings by 602,050 shares, bringing its total to 8,491,751 shares valued at approximately $116.8 million. Meanwhile, Neuberger Berman Group LLC reduced its stake by 312,219 shares, holding 4,475,492 shares worth around $61.5 million. T. Rowe Price Investment Management, Inc. cut its position by 698,724 shares, now holding 3,224,908 shares valued at about $44.3 million.

Stevanato Group S.p.A. Stock Down 12.6%

Shares of Stevanato Group S.p.A. traded near $18.39 on Friday. The company boasts a market cap of approximately $5.02 billion and a P/E ratio of 31.7. Over the past year, the stock has ranged from a low of $12.89 to a high of $28.00. It has a 50-day moving average of $17.39 and a 200-day moving average of $19.57. The company's beta is 0.776, indicating lower volatility compared to the market.

Analysts Set New Price Targets

On June 16, 2026, TD Cowen initiated coverage on Stevanato Group with a buy rating and a price target of $25. Earlier, on June 2, 2026, Wolfe Research assumed coverage with a buy rating and a $21 target. The consensus among analysts is a buy rating, with an average target price of $24.45 based on 10 opinions.

About Stevanato Group S.p.A.

Stevanato Group S.p.A., based in Piombino Dese, Italy, designs and produces products for the biopharmaceutical and healthcare industries. The company operates through two main segments: Biopharmaceutical and Diagnostic Solutions, and Engineering. It provides drug containment solutions, drug delivery systems, and various medical devices. Founded in 1949, Stevanato Group serves a global market, offering services from design to manufacturing and support.

Bottom Line

Sue-Jean Lin's recent purchase of shares in Stevanato Group S.p.A. is part of a broader pattern of insider activity. The company, known for its healthcare solutions, continues to attract attention from analysts and investors. With its strong market position and recent analyst ratings, Stevanato Group remains a company to watch. As always, remember that insider transactions are disclosed after they occur and may not reflect current positions.